Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Grandfather, 3-month-old granddaughter dead after violent dog attack Opinion: Why Marjorie ...

Google's Daniel Waisberg announced today at the Google Search Central event in Tel Aviv that Search Console will be gaining brand query filters. Plus, these filters will be AI-assisted, I am told.

Last June, LinkedIn CEO Ryan Roslansky took on a second job. Microsoft, the social network for business professionals’ owner since 2016, expanded his responsibilities to include Microsoft 365—the ...

As of Friday’s season-three premiere of Power Book IV: Force, Joseph Sikora has been playing volatile drug kingpin Tommy Egan in the Power universe for 12 years. With the final season of Force, he’s ...

Snap said on Thursday that it has signed a deal to integrate Perplexity’s AI search engine directly within Snapchat. As part of the deal, Perplexity will pay Snap $400 million in cash and equity. The ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...